NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine - https://archive.org/web/.

Oh No! No disclosure of Ohno drug company payment

Olympian Apolo Anton Ohno is a marketable commodity.

And drug company Teva Pharmaceuticals is riding those fast blades for all it can.

And media love reporting on how Ohno is now the “national face” of the exercise-induced brochospasm campaign sponsored by Teva, which gives the condition the acronym label of EIB.

Acronyms are hot in health care marketing these days: PE, ED, COPD, ACS, HSDD, PMDD, OAB – to name a few.  If you know all of these, well, we worry about you.

The Los Angeles Times jumped on EIB because of Ohno’s involvement, and published,5 Questions: Apolo Anton Ohno now making strides against asthma.”

Forget the questions for a minute.

Maybe one of the answers the Times should have provided was that Ohno is being paid by Teva for these appearances.

The Philadelphia Inquirer noted that:

One of the cultural trend-setters in the soul patch category, Olympic short-track speed skater Apolo Anton Ohno will try to help Teva Pharmaceuticals sell more of its asthma inhaler ProAir HFA.

Public education about exercise-induced bronchospasm and asthma can be a good thing.

We just think that news organizations should disclose it when people they interview are being paid by a drug company to do such interviews on behalf of its product line.

You might also like

Comments

Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.

Comments are closed.